Epstein-Barr viral capsid antigen and nuclear antigen produced by modified procedures were evaluated for use in measuring viral capsid antigen immunoglobulin M and Epstein-Barr virus nuclear antigen antibody responses in sera from patients with suspected Epstein-Barr virus infections. Viral capsid antigen production was stimulated with a phorbol ester, and the Epstein-Barr virus nuclear antigen cells were fixed in suspension to eliminate loss of antigen during the drying process. Both preparations proved to be sensitive and reliable.
Epstein-Barr virus (EBV), the causative agent of infectious mononucleosis (9) , stimulates heterophil antibodies in the sera of most patients during the acute stage of infection (4, 14) . These antibodies agglutinate sheep and horse erythrocytes and lyse bovine erythrocytes in the presence of complement, and detection of these antibodies is the diagnostic test of choice. However, EBV-specific antibody assays, as well as assays for cytomegalovirus, Toxoplasma gondii, and adenovirus, which can also cause infectious mononucleosis-like symptoms, are often required for heterophil-negative cases (10, 12) . Heterophil antibody is sometimes detectable for many months after infection (3) , which can be a source of diagnostic confusion, requiring additional serological tests for EBV to clarify the role of this agent in such problem cases.
Henle et al. (11) have shown that immunoglobulin G (IgG) and IgM antibodies to EBV viral capsid antigen (VCA) are stimulated in virtually 100% of EBV infections. These antibodies increase so rapidly that greater than or equal to fourfold IgG antibody rises to VCA can be demonstrated in only approximately 20% of the cases. VCA-IgM antibody is elevated during the acute stage of infection and drops to undetectable levels after convalescence (12) , so presence of this class of antibody is suggestive of current or recent infection. Antibody to EBV nuclear antigen (EBNA) is stimulated late in the course of infection and is detected 3 weeks to 6 months after onset (8 (17) or in equal volumes of methanol and acetone at -20°C for 3 min (12) . The authors of the latter procedure state that, when this method is used, the cover slip preparations usually contain some satisfactory areas, even when leakage of the antigens has occurred. However, we have found that the whole smear must be carefully screened before it can be determined that a serum lacks EBNA antibody, since the amount of antigen in the cells varies due to leakage. Thus, EBNA substrates are rather laborious to prepare, and reading the test is time consuming.
A tumor-promoter agent (TPA), 12-O-tetradecanoyl-phorbol-13-acetate, has been shown to stimulate the number of VCA-producing cells from 5 to 80% in a producer line (18) . We postulated that, if the number of VCA-producing cells was this much greater than the number of IgM-producing cells (usually 5 to 10% of the cell population), VCA-IgM antibody could then be reliably detected.
In cell biology studies, cells are often fixed in suspension to stabilize cellular components. An adaptation of this method was used to prepare EBNA smears to determine if loss of EBNA could be prevented. The present study evaluated these two antigen preparations for use in measuring VCA-IgM and EBNA antibody levels in sera from patients with suspected EBV infections. With rare exceptions, heterophil tests were either negative or had not been performed.
MATERIALS AND METHODS
VCA antigen preparation. The producer lymphoblast line, P3HR-1, was stored in liquid nitrogen until needed, to prevent loss of VCA production owing to extensive passage. Each stored ampoule contained cells from one 7-day-old bottle culture in 1 ml of growth medium with 10o dimethyl sulfoxide. For use, the cells from one ampoule were propagated in a 4-ounce (120-ml) prescription bottle containing 20 ml of Dulbecco modified Eagle medium (high glucose) with 10%o fetal bovine serum, 0.09% glutamine, 200 U of penicillin and 200 U of streptomycin per ml, and 3 p.g of amphotericin B per ml. Sodium bicarbonate was added as needed to maintain a pH of 7.2. At 7 days, 6 x 101 cells (78% viability by trypan blue stain) were transferred to each of three 4-ounce (120-ml) bottles containing growth medium with 20 ng of TPA (Consolidated Midland Corp., Brewster, N.Y.) per ml. A stock solution of TPA was prepared by reconstituting 10 mg in 1 ml of dimethyl sulfoxide; this was stored in 0.1-ml amounts at -20°C. A sample was reused provided that no precipitate formed when the solution was thawed. In 24 h, many of the cells in the TPA-treated cultures had attached to the glass. These cells were pipetted into the fluids at 3 days, and slides were prepared at 5 days.
VCA slide preparation. The cell suspension from the three bottle cultures of P3HR-1 cells was centrifuged at 450 x g for 5 min, the supernatant fluids were removed, and the cell pellet was reconstituted in 3 ml of 0.01 M phosphate-buffered saline, pH 7.2, containing 2% fetal bovine serum. Three cell spots, each approximately 3 mm in diameter, were applied to a slide, the cell density was checked microscopically, and the concentration was adjusted, if necessary, to give an almost confluent cell smear. Eight cell spots were made on each of 200 glass slides (gold seal; Clay Adams, Parsippany, N.J.). The slides were air dried, fixed in acetone at room temperature for 10 min, and stored at -60°C.
EBNA antigen preparation. The nonproducer Raji lymphoblast cells were also stored in liquid nitrogen until needed, maintained in the above growth medium without TPA, and split 1:3 at 7 days. The antigen was fixed at 14 days.
EBNA slide preparation. Ten-milliliter samples of Raji cell suspension from the three bottle cultures were centrifuged at 450 x g for 5 min. Immediately after the fluid was removed from a sample, 1 ml of a freshly prepared mixture of equal volumes of methanol and acetone was added dropwise to the cell pellet while the cells were gently agitated in a Vortex mixer. The fixed cells were pooled and centrifuged, and the supematant fluids were removed. The cell pellet was reconstituted in 3 ml of methanol-acetone, and the density was adjusted so that the cells in a 3-mm spot were almost confluent. The cell suspension was stored in a tightly stoppered tube at 4°C. Eight spots per slide were made on the day that EBNA antibody tests were performed, and the slides were air dried at room temperature for 30 min before use.
Immunofluorescence procedures. A 1:8 dilution of each test serum was absorbed with equal volumes of glutaraldehyde cross-linked human IgG for 1 h at 35°C to remove rheumatoid factor before being tested for the presence of VCA-IgM antibody (1). The IgM (6), IgG (2), and ACIF (13) tests were performed as previously described. Sera screened for EBNA antibody were tested in duplicate by the indirect immunofluorescence method on EBNA slides to detect antinuclear antibody, which would mask EBNA staining. The cell smears were not allowed to dry during the ACIF procedure for EBNA antibody determinations. Excess moisture around the smears was aspirated, and the appropriate reagent was applied immediately.
RESULTS
Approximately 70% of the TPA-stimulated P3HR-1 cells fluoresced when reacted with VCA-IgM-or VCA-IgG-positive sera (Fig. 1A) . Five percent of the cells reacted to varying degrees of brightness with the anti-IgM conjugate alone (Fig. 1B) . Because of this marked contrast between the numbers of VCA-and IgM-producing cells, even low levels of IgM antibody could be easily detected.
In the ACIF test for EBNA antibody, 100% of the cells (except the dead ones) in every smear tested showed dense nuclear fluorescence with positive sera (Fig. IC) . Variability in staining intensity within a smear, which would indicate leakage of the antigen, was not observed. This observation is in contrast to the uneven staining patterns encountered with the previous method of preparing EBNA slides (Fig. 1D) . Either no fluorescence or faint diffuse staining was visible with negative sera. The reliability of this antigen greatly facilitated the reading of the EBNA antibody assays.
The improved antigen preparations were evaluated in tests on 122 sera from patients with recent and past EBV infections. Twenty patients possessed antibody patterns consistent with recent EBV infection. The ages of the patients ranged from 1 to 62 years (Table 1) The patients examined in this study, with the exception of patient 18, were heterophil negative, and all were diagnostic problem cases. Although the ACIF test requires an additional step to that needed for the indirect immunofluorescence test, it is not a difficult procedure. In our experience, drying of the cell smears between the addition of reagents may result in a loss in sensitivity and should be avoided. Substituting guinea pig serum for human serum eliminates the problem of locating an EBV-negative serum source for complement. After the working dilution of a new lot of freshly reconstituted guinea pig complement is determined, the complement can be dispensed in appropriate working volumes and stored at -60°C, and the amount needed for the test can be thawed imme- Patients presenting with lymphatic disease who are heterophil negative and for whom other infections have been ruled out are diagnostic problems for the clinician, especially when lymphoma is a possibility. It is highly desirable that additional, reliable serological tests for EBV be available for studying these problem cases. Tests for measuring VCA-IgM and EBNA antibodies are within the capability of diagnostic microbiology laboratories, and the two antigens evaluated in this study were shown to be sensitive and reliable. It is hoped that similar reagents will soon become available through commercial sources.
